Sebastian Nikhil T, Raj Rohit, Prasad Rahul, Barney Christian, Brownstein Jeremy, Grecula John, Haglund Karl, Xu-Welliver Meng, Williams Terence M, Bazan Jose G
Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, United States.
Intermountain Radiation Oncology, Provo, UT, United States.
Front Oncol. 2020 Nov 5;10:598873. doi: 10.3389/fonc.2020.598873. eCollection 2020.
Neutrophil-lymphocyte ratio (NLR) has been associated with mortality in non-small cell lung cancer (NSCLC), but its association with recurrence in locally advanced NSCLC (LA-NSCLC), specifically, is less established. We hypothesized pre- and posttreatment NLR would be associated with recurrence and mortality.
We studied the association of pretreatment NLR (pre-NLR) and posttreatment NLR at 1 (post-NLR) and 3 months (post-NLR) with outcomes in patients with LA-NSCLC treated with chemoradiation. Pre-NLR was dichotomized by 5, an cutoff previously shown to be prognostic in LA-NSCLC. Post-NLR and post-NLR were dichotomized by their medians.
We identified 135 patients treated with chemoradiation for LA-NSCLC between 2007 and 2016. Median follow-up for living patients was 61.1 months. On multivariable analysis, pre-NLR ≥ 5 was associated with worse overall survival (HR = 1.82; 95% CI 1.15 - 2.88; p = 0.011), but not with any recurrence, locoregional recurrence, or distant recurrence. Post-NLR ≥ 6.3 was not associated with recurrence or survival. Post-NLR ≥ 6.6 was associated with worse overall survival (HR = 3.27; 95% CI 2.01- 5.31; p < 0.001), any recurrence (HR = 2.50; 95% CI 1.53 - 4.08; p < 0.001), locoregional recurrence (HR = 2.50; 95% CI 1.40 - 4.46; p = 0.002), and distant recurrence (HR = 2.53; 95% CI 1.49 - 4.30; p < 0.001).
Pretreatment NLR is associated with worse overall survival and posttreatment NLR is associated with worse survival and recurrence. These findings should be validated independently and prospectively studied.
中性粒细胞与淋巴细胞比值(NLR)已被证明与非小细胞肺癌(NSCLC)的死亡率相关,但它与局部晚期NSCLC(LA-NSCLC)复发的相关性,尤其是相关性尚不明确。我们假设治疗前和治疗后的NLR与复发和死亡率相关。
我们研究了接受放化疗的LA-NSCLC患者治疗前NLR(pre-NLR)以及治疗后1个月(post-NLR)和3个月(post-NLR)的NLR与预后的关系。pre-NLR以5为界进行二分法划分,该临界值先前已被证明在LA-NSCLC中具有预后意义。post-NLR和post-NLR以其各自的中位数进行二分法划分。
我们纳入了2007年至2016年间135例接受放化疗的LA-NSCLC患者。存活患者的中位随访时间为61.1个月。多变量分析显示,pre-NLR≥5与较差的总生存期相关(HR = 1.82;95% CI 1.15 - 2.88;p = 0.011),但与任何复发、局部区域复发或远处复发均无关。post-NLR≥6.3与复发或生存无关。post-NLR≥6.6与较差的总生存期相关(HR = 3.27;95% CI 2.01 - 5.31;p < 0.001)、任何复发(HR = 2.50;95% CI 1.53 - 4.08;p < 0.001)、局部区域复发(HR = 2.50;95% CI 1.40 - 4.46;p = 0.002)和远处复发(HR = 2.53;95% CI 1.49 - 4.30;p < 0.001)。
治疗前NLR与较差的总生存期相关,治疗后NLR与较差的生存期和复发相关。这些发现应进行独立验证并进行前瞻性研究。